RBC Capital reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) with a price target of $490. Earlier Intercept announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Trader Talk

Barclays Starts Intercept Pharmaceuticals (ICPT) at OverweightMay 21, 2015 6:35 AM Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Wedbush Amid Trial DesignMay 19, 2015 12:53 PM BofA/Merrill Lynch Downgrades Intercept (ICPT) to Neutral on Lack of CatalystsMay 19, 2015 11:51 AM Intercept (ICPT) NASH Study to be Larger, Riskier and Delayed, Leerink Partners SaysMay 19, 2015 11:51 AM BMO Capital Says Buy Intercept Pharmaceuticals (ICPT) on Weakness Related to Trial DesignMay 19, 2015 11:03 AM Intercept's (ICPT) OCA Ph3 Trial Design or Size Not Seen as Surprise - Deutsche BankMay 19, 2015 8:36 AM Intercept Pharma (ICPT) Announces Design of OCA Phase 3 in NASH with Liver FibrosisMay 19, 2015 6:06 AM Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASHMay 19, 2015 6:00 AM